树突状细胞基因修饰疗法在1型糖尿病治疗中的应用研究

Application of gene-modified dendritic cell therapy in the treatment of type 1 diabetes

树突状细胞（dendritic cells，DC）是已知功能最强的专职抗原提呈细胞（antigen presenting cell ，APC），其最大特点是刺激初始T细胞（naive T cells）的活化与增殖。DCs不仅在机体抗感染、肿瘤等免疫应答过程发挥作用，同时维持中枢耐受和外周耐受，防止自身免疫病的发生发展。Ⅰ型糖尿病（type 1 diabetes ，T1D）是一种常见的自身免疫病，由免疫耐受异常所致，其治疗存在巨大挑战。DCs中多种基因表达和功能异常与T1D密切相关，因此人们尝试修饰DCs相关基因治疗T1D。

Dendritic cells （DCs） are known as the most potent professional antigen presenting cell （APC）. The most important feature of DCs is to stimulate the activation and proliferation of the na？ve T cells.DCs play a unique role in the immune system, which participate not only in anti-infection, anti-tumor and other immune response process of the organism, but also in the maintenance of central tolerance and peripheral tolerance to prevent the development of autoimmune diseases.Type 1 diabetes （T1D） is a common autoimmune disease, triggered by dysfunction of immune tolerance.While the of T1D treatment is still a huge challenge.Since the abnormality of various gene expression and function in DCs are closely related with T1D, scientists try to treat T1D by modifying the DCs-related gene.